Loading...
XNYS
INSP
Market cap4.50bUSD
May 16, Last price  
152.67USD
1D
1.99%
1Q
-17.75%
IPO
523.91%
Name

Inspire Medical Systems Inc

Chart & Performance

D1W1MN
No data to show
P/E
84.15
P/S
5.61
EPS
1.81
Div Yield, %
—
Shrs. gr., 5y
5.11%
Rev. gr., 5y
57.80%
Revenues
803m
+28.49%
8,012,00016,427,00028,567,00050,593,00082,050,000115,381,000233,394,000407,856,000624,799,000802,804,000
Net income
54m
P
-21,337,000-18,528,000-17,511,000-21,828,000-33,243,000-57,203,000-42,042,000-44,881,000-21,153,00053,509,000
CFO
130m
+428.32%
-22,254,000-17,949,000-15,791,000-18,694,000-32,846,000-53,045,000-20,119,00011,569,00024,653,000130,246,000
Dividend
Jan 09, 20089 USD/sh
Earnings
Aug 04, 2025

Profile

Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
URL
https://www.inspiresleep.com/
IPO date
May 03, 2018
Employees
755
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
802,804
28.49%
624,799
53.19%
407,856
74.75%
Cost of revenue
237,114
665,070
455,448
Unusual Expense (Income)
NOPBT
565,690
(40,271)
(47,592)
NOPBT Margin
70.46%
Operating Taxes
4,944
1,247
613
Tax Rate
0.87%
NOPAT
560,746
(41,518)
(48,205)
Net income
53,509
-352.96%
(21,153)
-52.87%
(44,881)
6.75%
Dividends
Dividend yield
Proceeds from repurchase of equity
(75,000)
13,950
259,577
BB yield
1.32%
-0.23%
-3.67%
Debt
Debt current
1,336
Long-term debt
60,078
74,538
15,072
Deferred revenue
Other long-term liabilities
148
(23,500)
146
Net debt
(456,463)
(394,980)
(445,505)
Cash flow
Cash from operating activities
130,246
24,653
11,569
CAPEX
(39,123)
(23,629)
(9,096)
Cash from investing activities
(113,122)
(294,822)
(19,596)
Cash from financing activities
(52,393)
13,950
235,077
FCF
485,046
(116,530)
(52,747)
Balance
Cash
445,546
460,375
451,413
Long term investments
70,995
9,143
10,500
Excess cash
476,401
438,278
441,520
Stockholders' equity
(291,348)
(344,593)
(324,327)
Invested Capital
1,011,230
943,299
829,353
ROIC
57.38%
ROCE
78.58%
EV
Common stock shares outstanding
30,543
29,302
28,072
Price
185.38
-8.87%
203.43
-19.24%
251.88
9.48%
Market cap
5,662,112
-5.01%
5,960,937
-15.70%
7,070,712
12.73%
EV
5,205,649
5,565,957
6,625,207
EBITDA
572,240
(37,425)
(45,734)
EV/EBITDA
9.10
Interest
22
1,677
Interest/NOPBT
0.00%